Literature DB >> 31104014

The Nucleus Basalis of Meynert and Its Role in Deep Brain Stimulation for Cognitive Disorders: A Historical Perspective.

Philippos Koulousakis1,2, Pablo Andrade3,2, Veerle Visser-Vandewalle1,2, Thibaut Sesia1,2.   

Abstract

The nucleus basalis of Meynert (nbM) was first described at the end of the 19th century and named after its discoverer, Theodor Meynert. The nbM contains a large population of cholinergic neurons that project their axons to the entire cortical mantle, the olfactory tubercle, and the amygdala. It has been functionally associated with the control of attention and maintenance of arousal, both key functions for appropriate learning and memory formation. This structure is well-conserved across vertebrates, although its degree of organization varies between species. Since early in the investigation of its functional and pathological significance, its degeneration has been linked to various major neuropsychiatric disorders. For instance, Lewy bodies, a hallmark in the diagnosis of Parkinson's disease, were originally described in the nbM. Since then, its involvement in other Lewy body and dementia-related disorders has been recognized. In the context of recent positive outcomes following nbM deep brain stimulation in subjects with dementia-associated disorders, we review the literature from an historical perspective focusing on how the nbM came into focus as a promising therapeutic option for patients with Alzheimer's disease. Moreover, we will discuss what is needed to further develop and widely implement this approach as well as examine novel medical indications for which nbM deep brain stimulation may prove beneficial.

Entities:  

Keywords:  Acetylcholine; Alzheimer’s disease; deep brain stimulation; nucleus basalis zzm321990of Meynert

Year:  2019        PMID: 31104014     DOI: 10.3233/JAD-180133

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  7 in total

Review 1.  Developing Collaborative Platforms to Advance Neurotechnology and Its Translation.

Authors:  David A Borton; Heather E Dawes; Gregory A Worrell; Philip A Starr; Timothy J Denison
Journal:  Neuron       Date:  2020-10-28       Impact factor: 17.173

2.  Meynert nucleus-related cortical thinning in Parkinson's disease with mild cognitive impairment.

Authors:  Siming Rong; Yan Li; Bing Li; Kun Nie; Piao Zhang; Tongtong Cai; Mingjin Mei; Lijuan Wang; Yuhu Zhang
Journal:  Quant Imaging Med Surg       Date:  2021-04

3.  TrkA-mediated endocytosis of p75-CTF prevents cholinergic neuron death upon γ-secretase inhibition.

Authors:  María Luisa Franco; Irmina García-Carpio; Raquel Comaposada-Baró; Juan J Escribano-Saiz; Lucía Chávez-Gutiérrez; Marçal Vilar
Journal:  Life Sci Alliance       Date:  2021-02-03

Review 4.  Alzheimer's disease: An evolving understanding of noradrenergic involvement and the promising future of electroceutical therapies.

Authors:  Cody Slater; Qi Wang
Journal:  Clin Transl Med       Date:  2021-04

Review 5.  Neuroimaging evaluation of deep brain stimulation in the treatment of representative neurodegenerative and neuropsychiatric disorders.

Authors:  Shichun Peng; Vijay Dhawan; David Eidelberg; Yilong Ma
Journal:  Bioelectron Med       Date:  2021-03-30

6.  The brain of the tree pangolin (Manis tricuspis). VIII. The subpallial telencephalon.

Authors:  Aminu Imam; Adhil Bhagwandin; Moyosore S Ajao; Paul R Manger
Journal:  J Comp Neurol       Date:  2022-06-16       Impact factor: 3.028

Review 7.  Neurochemical organization of the ventral striatum's olfactory tubercle.

Authors:  Hillary L Cansler; Katherine N Wright; Lucas A Stetzik; Daniel W Wesson
Journal:  J Neurochem       Date:  2020-01-07       Impact factor: 5.372

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.